Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate for melancholic depression
ACTRN12613000209796Phase 3Recruiting
- Sponsor
- University of New South Wales
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methylphenidate, desvenlafaxine and dosulepin in melancholia and major depressive disorder (MDD) (3 arms), sponsored by University of New South Wales. Primary endpoints: Improvement in depressive severity by QIDS responder and remission rates and Depressive symptom severity by HAM-D. Started Apr 2013; status: recruiting.
02
Drugs
methylphenidatedesvenlafaxinedosulepin
03
Conditions
melancholiamajor depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12613000209796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000209796.